Clarus Therapeutics Company

Clarus Therapeutics is a biopharmaceutical company that is dedicated to addressing unmet medical needs through the development of androgen replacement and metabolic therapies. It charted a new course for men’s health with JATENZO® (testosterone undecanoate) Capsules CIII, filling a void in the market by developing and launching an oral testosterone replacement therapy.
Technology: United States
Industry: Hormonal Health
Headquarters: Northbrook, Illinois, United States
Founded Date: 2003-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 4
Total Funding: $122,000,000
Estimated Revenue: $10M to $50M
Last Funding Date: 2022-04-25
Last Funding Type: Post-IPO Equity

Visit Website
admin@clarustherapeutics.com
https://twitter.com/Clarus_Thera
Register and Claim Ownership